Hypercoagulable State and Glycemic Control in Diabetic Patients with Malignancy

Sry Suryani Widjaja\textsuperscript{1}, Muhammad O. K. Syahputra\textsuperscript{1}, Almaycano Ginting\textsuperscript{2}

\textsuperscript{1}Biochemistry Department, Medical Faculty, Universitas of Sumatera Utara, Medan, Indonesia; \textsuperscript{2}Clinical Pathology Department, Medical Faculty, Universitas of Sumatera Utara, Medan, Indonesia

Abstract

BACKGROUND: Diabetes and malignancy are two chronic diseases that have a major impact on the healthy population, both contribute to the increase of morbidity and mortality of the patients. Diabetes presented with hyperglycemia due to insufficiency or resistance of insulin has been associated with an increased risk of thrombosis. Malignancy or cancer is number two killer in the developing countries. One of the most common cause of death in cancer despite the disease itself is thrombosis, which occurred frequently as cancer cause changes in tumor biology, abnormal vascularisation, endothelial dysfunction, activation of coagulation and inflammation. Poor glucose control reflects by HbA1C has a significant correlation with a hypercoagulable state.

AIM: This study was to evaluate the relation between hypercoagulable state and glycemic control in diabetic patients with malignancy.

METHODS: This is a case control study, eighty samples diabetes (40 samples were diabetes with malignancy) were collected from private hospitals and clinics. HbA1C, blood glucose level and Ddimer were measured.

RESULTS: The forty five percent of the blood glucose level of the samples was not well controlled. The endothelial cell dysfunction, haemostatic disorders, hypercoagulable state and thrombosis were the main complications that increase the morbidity in diabetes [4]. Malignancy or cancer is number two killer in developing countries after infectious diseases. One of the most common cause of death in cancer despite the disease itself is thrombosis [5] which occurred occurred frequently as cancer cause changes in tumor biology, abnormal vascularisation, endothelial dysfunction, activation of coagulation and inflammation, besides the cancer itself causes increase activity of the procoagulant factors such as tissue factors, platelets and leucocytes. These explain the pathogenesis of thrombosis in cancer patients [6], [7]. Tumor tissue can activate blood coagulation and malignancy transformation are also involved in the...
regulation of coagulant factors in tumor cells [8].

Patients with malignancy and DM shared the same variety of co-morbid which can increase morbidity and death, one of the most common is thrombosis that involving both the arteries and veins. Abnormalities in endothelial cells and a tendency of thrombosis may cause atherosclerosis and its complications. In normal circumstances endothelial cells produce the substances needed to maintain blood vessel homeostasis and preventing thrombosis [9].

Overweight and obesity that affect the majority of adults are increasing rapidly worldwide, driving the global diabetes epidemic [9]. Increase in body fat is generally associated with increased risk of metabolic diseases like diabetes type 2 [10]. Body mass index were used to determine the presence or absence of obesity related comorbid disease [11].

This study was aimed to evaluate the relation between hypercoagulable state and glycemic control in diabetic patients with malignancy.

Methods

This is a case control study, eighty samples diabetes (40 samples were diabetes with malignancy) were collected from private hospitals and clinics. Malignancy cases were all solid tumor, diagnosed with pathology report, and diabetes was determined with the blood glucose ad random above 140 mg/dl and HbA1C.

**Laboratory measurements**

HbA1C was measured using an HPLC assay, blood glucose using spectrophotometry, hypercoagulable state was estimated by determining the Ddimer level using ELISA (Enzyme Linked immunosorbent assay).

Body mass index were determined by calculating body weight and height according to the standardized protocols [24]. All datas were analyzed by using SPSS 22.

**Ethics, consent, and permissions**

This study has been approved by the Medical Ethical Committee of Medical Faculty University of Sumatera Utara Medan Indonesia. All participants were provided with written informed consent before study.

### Results

Eighty samples with diabetes, in which 40 samples were with malignancy, were recruited.

**Table 1: Characteristic of the diabetes with malignancy samples**

|          | N   | Range | Minimum | Maximum | Mean  | Std Deviation |
|----------|-----|-------|---------|---------|-------|---------------|
| HbA1c   | 40  | 8.70  | 5.4     | 14.1    | 8.5   | 2.6           |
| Blood glucose | 40  | 465   | 92      | 557     | 242   | 122           |
| Ddimer  | 40  | 4.28  | 2.2     | 4.5     | 3.1   | 1.04          |
| BMI     | 40  | 23.37 | 14      | 38      | 25    | 4.08          |
| Age     | 40  | 40    | 45      | 65      | 60    | 8.9           |

In this group they were 40 % male and 60 % female with the ages range from 45 years to 85 years old. Forty five percent of the blood sugar of the patients were poorly controlled. Sixty-two-point five percent of the patients have normal BMI, 27.5% overweight and 2.5% underweight, less are obese patients.

**Table 2: Characteristic of the diabetes samples**

|          | N   | Range | Minimum | Maximum | Mean  | Std Deviation |
|----------|-----|-------|---------|---------|-------|---------------|
| HbA1c   | 40  | 10.3  | 2.4     | 12.7    | 7.6   | 2.3           |
| Blood glucose | 40  | 552   | 83      | 635     | 260   | 105.53        |
| Ddimer  | 40  | 4.4   | .13     | 4.5     | 1.3   | 1.1           |
| BMI     | 40  | 19    | 19      | 39      | 25    | 5             |
| Age     | 40  | 36    | 37      | 73      | 57    | 8.8           |

In the diabetic group there were 40 % male and 60% female. Forty five percent of the samples blood glucose was not well controlled as in the diabetes with malignancy group. Sixty five percent of the samples in this group were normoweight, overweight 20% and obese 10%, no underweight was found in this group.

The Ddimer levels were elevated in groups, 60% in the diabetes with malignancy group and 75% in the diabetes group. Mann-Whitney U test was used to analyze the HbA1c and Ddimer level between the diabetes patients and diabetes with malignancy patients, and it did not showed statistical significant (p = 0.08, p = 0.44). Correlation was calculated using the Spearman’s Rho correlation, and there was significant correlation between HbA1C and Ddimer (p=0.046), blood glucose and age (p = 0.017).

In both group most of the samples were normoweight (60-62.5%), only in the diabetes with malignancy group got the underweight samples (2.5%).

### Discussion

In this study, around forty five percent of the samples’ blood glucose were poorly controlled, this may because of the bad compliance, the disease itself like malignancy and medications. The chronic
uncontrollable glucose levels will worsen the hypercoagulable state, this can be seen from the DDimer levels that elevated in both groups, and from the statistical significant of the correlation between HbA1C and DDimer.

Body mass index did not showed any correlation with another variable in this study, maybe most of the samples were normoweight.

In conclusion, most of the blood glucose levels were not well controlled in both groups. This should be encouraged in the health care system to improve the control of blood glucose. Both groups showed hypercoagulable state which can be seen from elevated of the DDimer though did not showed statistical significant between group.

There was statistical correlation between HbA1C and DDimer, this should be an issue to be aware as chronic hyperglycemia will increased the risk of hypercoagulable, also the morbidity and mortality rate in diabetes with malignancy patients.

References

1. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus FEMS Immunol Med Microbiol. 1999; 26:256-65. https://doi.org/10.1111/j.1574-695X.1999.tb01397.x PMid:10575137

2. Atkins RC, Zimmet P. Diabetic kidney disease: Act now or pay later. Saudi J Kidney Dis Transpl 2012; 21:217-21. https://www.ncbi.nlm.nih.gov/pubmed/22099002

3. Peleg AY, Weeraratna T, McCarthy JS, Davis TM. Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007; 23:3-13. https://doi.org/10.1002/dmr.682 PMid:16960917

4. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. Circulation. 2003; 108:1527-32. https://doi.org/10.1161/01.CIR.000091257.27563.32 PMid:14504252

5. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125:490-3. https://doi.org/10.1016/j.thromres.2009.12.023 PMid:20097409 PMCID:PMC2878879

6. Sheth RA, Hesketh R, Kong DS, et al. Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol. 2013; 24:1201-7. https://doi.org/10.1016/j.jvir.2013.03.034 PMid:23735316

7. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010; 102(1):S2-9. https://doi.org/10.1038/ajbc.6605599 PMid:20386546 PMCID:PMC3315367

8. Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Critical reviews in oncology/hematology. 2017; 118:79-83. https://doi.org/10.1016/j.critrevonc.2017.08.003 PMid:28917273

9. Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis. 1998; 9(4):297-306. https://doi.org/10.1097/00001721-199806000-00001

10. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes care. 2011; 34(6):1249-57. https://doi.org/10.2337/dc11-0442 PMid:21617109 PMCID:PMC3114340

11. World Health Organization. Obesity and Overweight Facts, 2007. www.who.int/mediacentre/factsheets/fs311/en/

12. Bays HE, Chapman RH, Grady S. SHIELD Investigators' Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007; 61(5):737-47. https://doi.org/10.1111/j.1742-1241.2007.01336.x PMid:17493087 PMCID:PMC1890993